Ketamine One Aims to Become a North American Mental Health Leader
Ryan Allway
July 12th, 2021
Psychedelics, Top News
Nearly one in five Americans were living with a mental illness or addiction in 2019, according to the National Institutes of Health. While the U.S. spends $16 billion on mental health treatments and ancillary services each year, challenges connecting with patients, significant adverse side effects, and other factors have made the problem difficult to overcome.
After decades of prohibition, emerging research suggests that psychedelics could play an essential role in treating mental health conditions. For example, a Johns Hopkins study found that two doses of psilocybin relieved major depressive disorder symptoms, and a recently approved ketamine treatment eliminated suicidal ideations in just two to four hours.
Let’s look at how KetamineOne Capital Ltd. (NEO: MEDI) (“Ketamine One” or the “Company”) plans to bring these treatments to patients and overcome some of the critical barriers in administering mental health treatments with technology.
Building a Physical Footprint
Ketamine One is building a network of clinics across the U.S. and Canada that will initially administer FDA and Health Canada-approved ketamine products. These products can treat anxiety, severe depression, post-traumatic stress disorder, chronic pain, and addiction.
The Company’s current portfolio consists of 16 clinics and four additional clinics under a letter of intent. Management believes that its assets will generate revenue of C$10 million in 2021. By the first quarter of 2022, the company hopes to have expanded to 30 clinics, making it one of the largest public companies providing ketamine-assisted therapies.
As psilocybin and other psychedelics treatments are approved, the Company will be well-positioned to expand its services within the same patient population. Based on early research, the safety and efficacy of these future treatments could make them a frontline treatment option for a wide range of mental health conditions.
Using Cutting-edge Technology
Ketamine One plans to use new technologies to solve some of the historical challenges facing mental health treatments. For example, the Company plans to connect with patients using cutting-edge telehealth technologies and wearables, making it easier for physicians and patients to keep in touch without making unnecessary trips to a clinic.
To support this facet of the business plan, the Company is designing its very own wearable device to track patient vitals before, during, and after psychedelic therapies. The data points from these devices could be invaluable in conducting clinical research, as well as fine-tuning treatment plans to optimize outcomes.
The Company’s MindScape facility in Texas also became one of the first centers of its kind to introduce immersive virtual reality (“IVR”) to enhance ketamine-based treatments. Over the coming quarters, Ketamine One plans to further develop its proprietary IVR platform for deployment across its entire North American network of clinics.
In addition to connecting with patients, the Company plans to leverage the data generated from its clinical network to guide industry research and identify opportunities. For example, Ketamine One could discover new therapeutics or treatment plans for specific mental health conditions, creating an opportunity to build an intellectual property portfolio.
Growing Through Partnerships
Ketamine One has established several partnerships to achieve its goals in the most capital-efficient way possible.
The Company has a 10-year agreement with Unifor, Canada’s largest private-sector union, to support its members, retirees, and eligible dependents. Under its exclusive contract, Ketamine One provides access to medical cannabis product insurance reimbursements and physician-led cannabinoid therapy, and now it’s expanding into mental health services.
The Company also recently acquired KGK Science, a leading clinical research company. KGK Science is a leading contract research organization that has produced 150 publications, executed over 400 clinical trials, and accumulated huge amounts of data. In 2020, this business generated $4.4 million in revenue, a figure that’s only expected to grow.
In addition to providing immediate revenue, Ketamine One plans to launch clinical studies to explore the potential for its proprietary IVR technology to improve treatment outcomes in patients. These kinds of studies could expand the company’s intellectual property portfolio and pave the way for licensing and royalty-based business models.
Looking Ahead
Ketamine One (NEO: MEDI) provides investors with a unique opportunity to participate in psychedelics. With plans to become the largest clinic network in North America, the Company has a compelling business plan that ventures beyond clinics to build value through wearables, telehealth, and data collection and analysis.
For more information, visit the company’s website or download their investor presentation.
Disclaimer
The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Alan Brochstein’s 420 Investor is the go-to community for investors to learn, explore, and profit from the marijuana companies. The main goal of 420 Investor is to provide real-time, objective information about the top marijuana companies in the market in order to help investors capitalize on cannabis.
Matthew Nordgren is an ambitious executive, dedicated philanthropist, and accomplished athlete who brings a unique passion to creating strategic alliances. He has breadth and depth of experience in finance, corporate development, and capital sourcing, as well as in building highly motivated teams of skilled professionals. In 2005, Mr. Nordgren received his education at the University […]
SinglePoint, Inc (SING) is a technology and investment company with a focus on acquiring companies that will benefit from the injection of growth capital and technology integration.
NanoSphere Health Sciences is a biotechnology company that has developed and is commercializing its patent-pending NanoSphere Delivery SystemTM, a ground breaking platform using nanotechnology for the delivery of biological agents such as cannabinoids, supplements, nutraceuticals and over-the-counter medications for the cannabis, pharmaceutical and animal health industries, and beyond.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
